$13.55
-0.40 (-2.87%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LYEL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, +4 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyNCT07188558Event free survivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel | Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed | 400 | Dec 2029 | ≤ 1,230 d | 2026-08-04 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaNCT05826535Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agentNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma | 270 | 2028-12-31 | in 865 d | 2026-05-28 |
| LYL273 for Patients With Relapsed or Refractory mCRCNCT05319314Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation studyOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: LYL273 | Colorectal Cancer | 155 | Jun 2028 | ≤ 681 d | 2026-06-09 |
| A Biomarker Screening Protocol for Participants With Solid TumorsNCT05891197observationalTo identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials | — | Terminatedsponsor's stated reason: Pipeline Reprioritization | — | Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 10 | 2025-02-05actual | — | 2025-07-01 |
| A Study to Investigate LYL845 in Adults With Solid TumorsNCT05573035Incidence of dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Pipeline Reprioritization | Biological: LYL845 | Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer | 39 | 2025-01-09actual | — | 2025-07-01 |
| A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)NCT06153095Phase I: Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), and other treatment-emergent adverse events (TEAEs).Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: IMPT-514, IMPT-514, IMPT-514 | Systemic Lupus Erythematosus, Lupus Nephritis | 0 | 2025-01-09actual | — | 2025-02-10 |
| A Study to Investigate LYL797 in Adults With Solid TumorsNCT05274451Evaluate incidence of dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Pipeline Reprioritization | Biological: LYL797 | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 57 | 2024-11-27actual | — | 2025-07-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19